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Abstract
Background: Sexual transmission accounts for the majority of HIV-1 infections. In over 75% of cases, infection is initiated by
a single variant (transmitted/founder virus). However, the determinants of virus selection during transmission are unknown.
Host cell-cell interactions in the mucosa may be critical in regulating susceptibility to infection. We hypothesized in this
study that specific immune modulators secreted by uterine epithelial cells modulate susceptibility of dendritic cells (DC) to
infection with HIV-1.
Methodology/Principal Findings: Here we report that uterine epithelial cell secretions (i.e. conditioned medium, CM)
decreased DC-SIGN expression on immature dendritic cells via a transforming growth factor beta (TGF-b) mechanism.
Further, CM inhibited dendritic cell-mediated trans infection of HIV-1 expressing envelope proteins of prototypic reference.
Similarly, CM inhibited trans infection of HIV-1 constructs expressing envelopes of transmitted/founder viruses, variants that
are selected during sexual transmission. In contrast, whereas recombinant TGF- b1 inhibited trans infection of prototypic
reference HIV-1 by dendritic cells, TGF-b1 had a minimal effect on trans infection of transmitted/founder variants
irrespective of the reporter system used to measure trans infection.
Conclusions/Significance: Our results provide the first direct evidence for uterine epithelial cell regulation of dendritic cell
transmission of infection with reference and transmitted/founder HIV-1 variants. These findings have immediate
implications for designing strategies to prevent sexual transmission of HIV-1.
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Introduction
Since it was initially reported over 25 years ago, HIV-1 infection
has remained the most challenging health issue [1]. Whereas tangible
progress has been made with regards to treatment and prevention
efforts [2], there is little knowledge about the biology of sexual
transmission, the predominant mode of HIV-1 acquisition [3,4]. This
presents a major hurdle for strategies to reduce mucosal transmission
of HIV-1, such as microbicides and vaccines. Therefore, defining the
determinantsofmucosaltransmissionremainsacriticalprioritytothe
prevention of sexual acquisition of HIV-1.
Sexual transmission is almost exclusively initiated by HIV-1
variants with tropism for the CCR5 co-receptor (R5 viruses) [5,6].
The mechanisms that facilitate preferential transmission of R5 viruses
are not fully understood. Further, recent studies examining sequence
composition of transmitted viruses indicate that infection is initiated
by a single variant in over 75% of heterosexual HIV-1 transmission
[6,7,8,9,10]. The genetic and biological characteristics of these
transmitted/founder variants are under investigation [6,9,11].
In the female reproductive tract (FRT) mucosa, a variety of
immune cell types are found, many of which are possible direct
targets for HIV-1 infection [12]. Target cells in the upper and lower
FRT include CD4+ T lymphocytes, macrophages, dendritic cells
(DC) and epithelial cells [13,14,15,16,17]. Despite their presence,
questions remain to be answered with regard to the initial target
cells for infection and how HIV-1 is propagated following mucosal
exposure. A spectrum of soluble immune mediators, including
cytokines, chemokines and growth factors, constitute a local milieu
in the sub-mucosa that regulates immune target cells [18]. With
regard to HIV-1 infection via the FRT, we and others have
demonstrated that these soluble mediators, most of which are
hormonally controlled, regulate the expression of receptors and co-
receptors that facilitate infection with HIV-1 [15,19,20].
Dynamic cell-cell communication in the FRT mucosa may
influence the efficiency of HIV-1 transmission. For example, we
previously described the presence of lymphoid aggregates in the
endometrium, within which are CD14+ cells in close proximity to
epithelial cells [15,21]. The close anatomical juxtaposition of these
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their function by overlying epithelial cells. Evidence for cell-cell
communication via local secretions is in part based on our findings
that secretions from primary human uterine epithelial cells (UEC)
[22,23] modulate the differentiation and maturation processes
leading to the generation of tolerogenic DC [24,25].
In previous studies, we determined the mechanisms by which
uterine epithelial cell conditioned medium (CM) modulates DC
function [24]. DC which were differentiated in the presence of CM
(i.e. CM-DC) had reduced surface expression of CD86 and CD83.
In contrast, expression of CD1a, CD80, HLA-DR, CD14 and
CD163 was not altered significantly with CM-DC relative to that
seen on control DC (i.e. Con-DC). Further, following activation
with TLR3 ligand (poly(I:C)) or TLR4 ligand (LPS) the expression
of CD80, CD86 and CD83 were decreased on CM-DC relative to
Con-DC. In addition, CM-DC responded to LPS or PIC
stimulation with enhanced IL-10 production. RT-PCR analysis
showed thatCM-DC significantlyincreasedexpressedofmRNAfor
indoleamine 2,3-Dioxygenase (IDO), an immune tolerance pro-
motingenzyme. Finally, in a mixed leukocyte reaction (MLR) assay,
CM-DC had significantly lower allogeneic proliferative responses
when compared to Con-DC. Interestingly, uterine epithelial cell
CM does not appear to induce the development of Langerhans cells
from monocytes, as indicated by the lack of expression of Langerin
and E-cadherin (data not shown). These initial findings underscore
the critical role of cell-cell interactions in regulating immune
responses in the endometrium.
Mucosal DC are believed to play an integral role in sexual
transmission of HIV-1. For example, DC express a variety of
attachment receptors including DC-SIGN that enable specific
binding to HIV-1 envelope proteins [26,27,28]. The captured virus
is then transferred to target cells across the virological synapse
established with DC, a process referred to as trans infection
[29,30,31]. In the FRT, DC-SIGN is expressed by subsets of DC
in the submucosa of the human vagina and endometrium [32,33].
Thus, mucosal DC are poised to facilitate the dissemination of virus
from the mucosal portal of entry. There is increasing recognition of
mucosal DC as a unique subset whose phenotype and functional
characteristics reflect specific local immune microenvironments
[34]. We therefore sought to define the molecular basis by which
epithelial cell-DC interactions regulate HIV-1 infection of the
endometrium. We hypothesized in this study that specific immune
modulators secreted by uterine epithelial cells drive the differenti-
ation of DC with altered susceptibility to HIV-1.
We report in this study that: 1) UEC secretions down-regulate
DC-SIGN expression on DC via a TGF-b-dependent mechanism,
2) UEC suppress the trans infection of both reference and
transmitted/founder HIV-1, and 3) Recombinant TGF- b1 exerts
a differential inhibitory effect in that it inhibits trans infection of
reference HIV-1 but has minimal inhibitory effect on trans
infection of transmitted/founder HIV-1 variants tested here.
These findings provide potential novel insight into the biology of
HIV-1 transmission in the FRT and suggest a previously
unidentified mechanism of DC-SIGN regulation. Whether
transmitted/founder viruses use unique trans infection pathways
that are separate and distinct from those used by reference HIV-1
remains to be determined.
Results
Uterine epithelial cell secretions decrease DC-SIGN on DC
by a TGF-b-dependent mechanism
We determined the effect of primary UEC secretions on DC-
SIGN expression by immature DC derived from highly purified
human blood monocytes. As seen in Figure 1A and B,
differentiation of DC for seven days in the presence of CM
decreased surface expression of DC-SIGN, with a range of
inhibition of 25–50% relative to Control DC (n=6). We found a
similar pattern of inhibition of DC-SIGN by CM obtained from
ECC-1, a well-differentiated uterine epithelial cell line [35]
(Figure S1). To more fully define the time interval necessary
for altering DC-SIGN expression, immature DC were acutely
treated with CM from ECC-1 or primary UEC for 48 hr prior to
FACS analysis of DC-SIGN expression. The acute treatment with
CM resulted in a similar down-regulation of DC-SIGN expression
(Figure S2). These results demonstrate the acute and chronic
effects of primary UEC CM on DC-SIGN expression.
We next performed experiments to identify the soluble factor in
CM responsible for inhibiting DC-SIGN expression. TGF-b was
evaluated as a candidate molecule due to its pivotal influence on
the development and functions of DC [36]. Recognizing that
polarized UEC secrete biologically active TGF- b (Figure S3 and
Figure S4), we assessed the role of TGF-b in CM-induced down-
regulation of DC-SIGN. DC were differentiated from monocytes
with CM in the presence or absence of a highly specific TGF-b
type 1 receptor antagonist (SB431542) [37]. As seen in Figure 1C
the inhibitory effect of CM on DC-SIGN expression was
completely abrogated by SB431542. To extend these findings,
DC were differentiated from monocytes for 7 days in the presence
or absence of increasing concentrations (0, 0.1, 1 and 10 ng/mL)
of recombinant human TGF-b1. TGF-b1 decreased the surface
expression of DC-SIGN on immature DC in a dose-dependent
manner (Figure 2A and 2B). Further, when DC were
differentiated with TGF-b1 in presence of the TGF-b receptor 1
kinase inhibitor, SB431542 (10 mM), the inhibitory effects of TGF-
b1 on DC-SIGN were blocked at all concentrations analyzed
(Figure 2C). Taken together, these results demonstrate that
biologically active TGF-b is present in uterine epithelial cell CM,
and that blockade of TGF-b signaling abrogates the inhibitory
effect of CM on DC-SIGN expression.
In other experiments, we determined the effect of CM obtained
from either polarized primary UEC or from ECC-1 on the
expression of CXCR4 and CCR5 by immature DC. For these
experiments, DC were differentiated for 7 days from monocytes in
the presence or absence of UEC CM. CM from primary UEC
increased the expression of CXCR4 on DC (p,0.05, n=4 donors)
(Figure S5 A). In contrast, whereas there was a trend towards
increased CCR5 expression on DC generated with CM, the effect
was not statistically significant upon analysis of DC from multiple
donors (p=0.062, n=4) (Figure S5 B). These findings indicate
that surface expression of HIV-1 co-receptor CXCR4 but not
CCR5 is enhanced by UEC derived secretions.
Epithelial Cell CM inhibits trans infection of HIV-1
reference strains and transmitted/founder HIV-1 variants
Our results showing the inhibitory effect of CM on DC-SIGN
expression implied that DC generated in the presence of CM (i.e.
CM-DC) might have reduced capacity for trans infection of HIV-1
relative to control DC (i.e. Con-DC). To directly test this
hypothesis, we performed HIV-1 trans infection assays using a
modification of a previously described protocol [38]. Immature
DC were pulsed with HIV-1 derived from infectious molecular
clones (IMC) expressing 6 different env genes, including transmit-
ted/founder envs [6,9], in an isogenic reporter backbone [39,40]
(Ochsenbauer et al, in preparation). Virus-pulsed DC were then
co-cultured with TZM-bl reporter cell line [41]. Virus infection of
TZM-bl cells was then assayed by measuring b-galactosidase
expression. Averaged data from five experiments are shown in
HIV Trans Infection of DC
PLoS ONE | www.plosone.org 2 December 2010 | Volume 5 | Issue 12 | e14306Figure 1. Conditioned medium (CM) from polarized uterine epithelial cells decreases DC-SIGN on Immature DC by a TGF-b
mechanism. Immature DC were differentiated from human monocytes with IL-4 and GM-CSF in the presence or absence of CM obtained from
polarized primary uterine epithelial cells (UEC). (A) Overlay histograms show expression of DC-SIGN by Control DC (light gray) or DC differentiated
with CM (dark gray). Staining with isotype control antibody is shown as unfilled histogram. (B) Averaged mean fluorescence intensity (MFI) values for
DC-SIGN expression by DC from individual donors (n=6) are presented as % MFI of Control DC 6 standard error of mean (SEM). * p=0.035. (C)
Blockade of TGF-b signaling abolishes the effect of CM on DC-SIGN expression. TGF-b was blocked with the TGF-b Receptor 1 kinase inhibitor
(SB431542). Average MFI values for triplicate analyses from a single representative experiment (n=3) are presented as % MFI relative to Control.
doi:10.1371/journal.pone.0014306.g001
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the envelope proteins of the reference viruses (BaL and YU-2)
(Figure 3A). To ensure that only trans infection was being
measured, controls carried out with each experiment included a)
the lack of infection of DC when the cells were incubated with
virus alone (cis infection) (Figure S6), b) pre-incubation of DC
with T20 (fusion inhibitor) and/or Nevirapine (nonnucleoside
reverse transcriptase inhibitor) for 1 hr prior to the addition of
virus (Figure S7 A), and c) simultaneous addition of T20 and/or
Nevirapine during co-culture of virus pulsed DC and TZM-bl
(Figure S7B). The lack of productive infection of DC with HIV-1
coupled with the findings that trans infection of HIV-1 to TZM-bl
was not significantly affected by pre-incubation of DC with T20
and Nevirapine or with AMD-3100 and TAK-779 prior to
infection, collectively excluded productive infection of DC as a
significant source of virus for trans infection.
To determine whether CM inhibited DC trans infection of
transmitted/founder viruses, a series of trans infection experiments
were carried out with HIV-1 expressing envelope proteins of four
different transmitted/founder variants: WITO, CH058, WEAU
and CH077. As seen in Figure 3B, and similar to that seen with
reference viruses (Figure 3A), CM from primary UEC decreased
trans infection of the transmitted/founder variants. These findings
were reproducible using DC from 5 donors in 5 separate
experiments (Table 1). With the exception of one transmitted
virus (CH058) which showed no inhibition in a single experiment,
inhibition ranged from 27–80%.
Transmitted HIV-1 variants are less susceptible to TGF-b1
inhibition of trans infection by DC
Having shown that TGF-b1 inhibited DC-SIGN expression by
immature DC, we sought to determine its role in DC-mediated
trans infection of HIV-1. For these experiments, DC were
differentiated from monocytes in the presence or absence of
recombinant TGF-b1 (10 ng/mL). This concentration corre-
sponds to peak production of TGF-b1 by epithelial cells in the
endometrium [42]. We found that DC generated in the presence
of TGF-b1, when incubated with TZM-bl cells, had reduced trans
infection of molecular HIV-1 clones expressing envelopes of
reference variants (BaL and YU-2) relative to that seen with
Control DC (n=5) (Figure 4A). In 5 experiments with BaL and
YU-2 env, inhibition (% Inhibition=100%-% transmission) ranged
from 12–69% and as indicated for each experiment, all TGF-b1
treated cells were significantly different from controls (p=0.01–
Figure 2. TGF-b1 inhibits DC-SIGN expression by DC. Immature DC were derived from human monocytes with IL-4 and GM-CSF in the
presence or absence of increasing concentrations of recombinant TGF-b1. (A) Overlay histograms for DC-SIGN expression. Filled histogram shows
specific staining for DC-SIGN. (B) Averaged mean fluorescence intensity (MFI) values for DC-SIGN expression (n=3 donors) are shown as % MFI
relative to control DC. (C) Expression of DC-SIGN by DC generated with TGF-b1 in the presence (black bars) or absence (gray bars) of TGF-b Receptor
1 kinase inhibitor (SB431542). * Indicates p,0.05 compared to Control DC.
doi:10.1371/journal.pone.0014306.g002
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expressing BaL and YU-2 envelopes, clones expressing envelopes
from WITO, CH058 and WEAU were relatively refractory to the
inhibitory effect of TGF-b1o ntrans infection by DC (Figure 4B).
Whereas inhibition by TGF-b1 ranged from ,1 to 43%, only 4
out of 15 values from 5 experiments with transmitted variants
significantly lower than those from controls (Table 2). The only
exception was CH077 whose trans infection was consistently
suppressed when DC were treated with TGF-b1 (4 out of 4
experiments) (Figure 4B and Table 2).
To more fully understand the mechanisms of CM and TGF-b1
mediated trans infection, additional experiments were conducted
using a well-established T cell line, NOMI [43,44]. Our goals in
these studies were: 1) to confirm the effects CM and TGF-b1o n
HIV-1 trans by DC, and 2) to determine the effect of antibody
blockade of DC-SIGN on trans infection of HIV-1 expressing
either reference or transmitted/founder envs. For these experi-
ments, DC were pulsed with HIV-1 reporter viruses (env-IMC-
lucR) expressing the Renilla luciferase reporter gene, and then co-
cultured with NOMI cells for 72 hr. Virus replication was
determined by measuring Renilla luciferase (LucR) activity.
When NOMI T cells were used as targets, CM-DC had
decreased capacity relative to Con-DC for trans infection of virus
expressing BaL and YU-2 envs (Figure 5A). These results were
consistent with those initially obtained with the TZM-bl system
(Figure 3A). Further experiments conducted with the NOMI
reporter system showed that CM decreased trans infection of virus
expressing WITO and CHO58 transmitted/founder envs
(Figure 5A). Unexpectedly, we found that CM had no effect on
trans infection of virus expressing WEAU and CHO77 transmit-
ted/founder envs (Figure 5A). This latter finding differed from
that obtained with TZM-bl cells as targets (Figure 3B).
TGF-b1 treatment of DC showed a slightly different profile on
HIV-1 trans infection when NOMI cells were used as targets
relative to that seen with TZM-bl as targets. In contrast to the
earlier observed inhibition of virus expressing reference BaL and
YU-2 envs by TGF-b1 when TZM-bl cells were used as targets
(Figure 4A), only YU-2 was significantly inhibited by TGF-b1
when NOMI cells were used to measure virus infection
(Figure 5B). Of the four transmitted/founder viruses analyzed,
only the trans infection of CHO58 was inhibited by TGF-b1
treatment of DC (Figure 5B), a result consistent with that
obtained when TZM-bl cells were used as targets (Figure 4B). An
expected finding was the lack of TGF-b1 inhibition of CHO77
with NOMI cells as targets. However, the lack of inhibition of trans
infection of virus expressing WEAU and WITO env by DC treated
with TGF-b1( Figure 5B) was consistent with the results initially
obtained with the TZM-bl reporter system (Figure 4B).
Having demonstrated that the expression of DC-SIGN on DC
is decreased by CM (Figure 1) and TGF-b1( Figure 2), we
examined the effect of DC-SIGN blockade on trans infection of
viruses expressing reference and transmitted/founder envs. For
these experiments, DC were pre-pretreated with antibody to DC-
SIGN prior to incubation with HIV-1. As seen in Figure 5,
blockade of DC-SIGN decreased trans infection of HIV-1 IMC
expressing reference YU-2 env, but had little to no significant effect
on trans infection of IMC expressing reference BaL env (or virus
expressing WITO, CH58, WEAU and CHO77 transmitted/
founder envs (Figure 5C).
Discussion
DC present in the mucosal tissues of the FRT may be integral to
the cellular and molecular processes that underlie immune
protection and possibly contribute to the sexual transmission of
HIV-1. Within the mucosa, the phenotype and functions of DC
are influenced by specific regulatory cues in the local milieu. The
aim of our study was to elucidate the molecular mechanisms by
which endometrial epithelial cells modulate HIV-1 infectivity of
DC. We report that primary UEC CM decreases the expression of
DC-SIGN on DC via a TGF-b-dependent mechanism. Further,
DC generated with epithelial secretions exhibited reduced trans
infection of HIV-1 expressing envelope proteins of reference (BaL
and YU-2) and of four transmitted/founder HIV-1 (WITO,
CH058, WEAU and CH077). In contrast, recombinant TGF-b1
inhibited DC-mediated trans infection of reference viruses but
failed to consistently inhibit trans infection of transmitted/founder
variants. Collectively, our findings provide unique and novel
insight into the nature of cell-cell interactions in the endometrial
mucosa, as well as the potential impact of such interactions on
HIV-1 capture and dissemination by DC within the FRT.
Our study shows that secretions from primary UEC down-
regulate the expression of DC-SIGN by immature DC. The results
we obtained with TGF-b receptor blockade and with recombinant
TGF-b1 support the hypothesis that the effects of primary UEC
secretions on DC-SIGN are at least in part attributable to TGF-b.
Whereas TGF-b has been previously shown to decrease the
Figure 3. Reduced trans infection of HIV-1 by DC cultured with
primary UEC CM. Shown is the effect of primary UEC CM on trans
infection by DC of HIV-1 infectious molecular clones encoding envelope
ectodomains (env-IMC) of reference HIV-1 (BaL or YU-2) (A)o r
transmitted/founder variants (B) (n=5 blood donors). HIV-1 trans
infection assay was performed using TZM-bl reporter cells as targets as
described in materials and methods. Unshaded histograms are Control
DC and the black histograms are CM DC. The data are presented as %
transmission 6 SEM (Calculated from 4 or 5 separate experiments: see
Table 1) of HIV-1 by CM DC relative to Control DC. * p,0.05,
** p,0.001.
doi:10.1371/journal.pone.0014306.g003
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directly link TGF-b derived from polarized uterine epithelial cells
with the regulation of DC-SIGN expression by DC. TGF-b is
known to be secreted in both an activated form and as an inactive
molecule bound to latency associated protein (LAP) [46]. Others
have shown that primary UEC secrete TGF-b [42,47]. Our
findings extend these studies, by using a highly sensitive and
specific bioassay [48], to demonstrate that primary UEC secrete
biologically active TGF-b. Overall, our findings demonstrate that
epithelial cells from the endometrium secrete bioactive TGF-b,
which exerts an inhibitory effect on immature DC during their
differentiation from myeloid precursors to lower surface expression
of DC-SIGN.
Our results indicate that CM from primary uterine epithelial
cells inhibits trans infection of HIV-1 by DC. Using the TZM-bl
reporter cell line as target, we found that CM inhibited trans
infection of prototypic R5 reference viruses (BaL and YU-2) and
transmitted/founder variants (WITO, CH058, CH077 and
WEAU). Similarly, in an alternative approach that utilizes
CD4+/CCR5+ T cells, the NOMI reporter cell line [43,44] as
target, CM inhibited trans infection of reference viruses and two of
the transmitted viruses (WITO and CHO58). Unexpectedly, trans
infection of WEAU and CHO77 was not inhibited by CM when
NOMI cells were used targets. The mechanisms that underlie this
observation are uncertain, and may involve both inherent
properties of the viruses as well as disparate specific mechanisms
by which DC transfer HIV-1 to TZM-bl or T cells. Nevertheless,
that transmitted HIV viruses were inhibited, as were reference
strains, is of particular importance given the new paradigm that
sexual transmission of HIV-1 is most likely a single variant in over
75% of transmissions [6,7,8,9,10]. Epidemiological studies have
shown that the rate of male-to-female transmission of HIV-1 is
relatively low compared to other sexually transmitted infections
(STIs) [49,50]. While the reasons for this low rate of HIV mucosal
transmission are likely to be multi-factorial, our findings suggest
that soluble immune mediators produced by epithelial cells reduce
the capacity of DC to disseminate HIV-1 in the endometrium.
The recognition that dyes and semen placed in the vagina are
rapidly distributed throughout the FRT [51,52,53] is supportive of
the evidence that both cell-free and cell-associated HIV-1 enters
the lumen of the cervix, uterus and the Fallopian tube during a
window of vulnerability [54]. Our studies suggest that during
male-to-female transmission, secretions derived from epithelial
cells of the FRT act to reduce the overall efficiency of HIV-1
transmission by inhibiting DC-mediated trans infection.
In contrast to our findings with CM, TGF-b1 inhibited DC-
mediated trans infection of the reference R5 HIV-1 strains (BaL
and YU-2), but failed to consistently inhibit trans infection of
transmitted/founder variants. These studies indicate that epithelial
cell secretions (CM) are able to inhibit transmitted viruses in ways
beyond that seen with TGF-b1 alone. Whether the differences
observed between reference and transmitted viruses are due to
inherent binding affinities of the viruses for DC-SIGN remain to
be determined. However, by analyzing the effects of TGF-b1, the
present studies have unmasked a level of complexity in
endometrial epithelial cell and DC function not previously
recognized. Specifically, the failure of TGF-b1 to inhibit trans
infection of transmitted/founder viruses suggests that viral trans
infection can occur independently of DC-SIGN. One possible
explanation for these observations is that several isoforms of TGF-
b1, TGF-b2 and TGF-b3 [47] are present in uterine epithelial cell
CM. It is possible that synergistic interactions between these
isoforms confer primary UEC CM with a broader inhibitory
activity on DC-mediated trans infection of HIV-1.
We have previously characterized the spectrum of soluble
factors produced by polarized uterine epithelial cells in culture,
and found that in addition to TGF-b, these cells secrete a number
of cytokines and chemokines [22,23,55,56,57]. Some of these
Table 1. Effect of CM on DC-mediated trans infection of HIV-1.
% Transmission (trans) of HIV-1 by CM DC
(Transmission by Control DC set at 100%)
Donor 1 Donor 2 Donor 3 Donor 4 Donor 5
Reference HIV-1
BaL 61.7 (4.7) 11.9 (2.7) 31.0 (4.8) 74.7 (1.0) 75.7 (4.7)
p value 0.007 0.006 0.004 0.022 0.046
YU-2 47.8 (3.4) 21.5 (3.7) 23.6 (4.1) 50.2 (1.7) 44.2 (3.4)
p value 0.010 0.0120 0.012 0.041 0.019
Transmitted/Founder HIV-1
WITO 68.6 (3.5) 32.2 (7.1) 48.9 (4.7) 34.0 (5.6) ND
p value 0.001 0.002 0.021 0.025
CH058 141.5 (21.0) 20.6 (1.0) 55.0(6.9) 43.9 (1.0) 48.3 (7.9)
p value 0.213 0.032 0.016 0.002 0.024
WEAU 73.0 (5.7) 35.7 (3.8) 46.3 (6.4) 57.1 (9.0) 65.7 (7.0)
p value 0.067 0.017 0.058 0.026 0.088
CH077 37.2 (6.4) 27.3 (6.9) 19.2 (4.5) 33.2 (3.6) ND
p value 0.006 0.014 0.003 0.023
Summarized data from individual experiments showing the effect of CM on trans infection of HIV-1 by DC. DC were derived from monocytes in the
presence or absence of CM obtained from primary UEC CM following 48 hr of culture. DC-mediated trans infection of HIV-1 infectious molecular clones (env-IMC)
expressing reference env (BaL and YU-2) or transmitted virus env (WITO, CH058, WEAU and CH077) respectively was determined using TZM-bl cells as targets for virus
infection. Results are presented as percent transmission 6 SEM of HIV-1 by CM DC relative to Control DC (value set at 100%). ND, indicates not determined.
doi:10.1371/journal.pone.0014306.t001
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TSLP and hepatocyte growth factor (HGF), are known to directly
affect the differentiation and/or activation of DC
[58,59,60,61,62,63]. It is therefore likely that a number of soluble
factors produced by uterine epithelial cells, in addition to TGF-b,
interact in a specific manner to exert the observed inhibitory effect
on HIV-1 trans infection.
An additional candidate molecule that could mediate the effects
of uterine epithelial cell CM on HIV-1 trans infection is Activin A.
As a member of the TGFb superfamily [64], Activin A is produced
by human uterine epithelial cells [65,66,67]. A recent study showed
that Activin A induces the differentiation of LCs from human
monocytes [68]. In preliminary experiments, we examined the
effect of Activin A on HIV-1 trans infection by DC. We found that
DC differentiated in the presence of recombinant Activin-A (i.e.
Activin-DC) had reduced capacity for trans of IMC expressing
envelopes of BaL env and YU-2 env-expressing reference viruses
(Figure S8). Similarly, Activin-DC displayed reduced trans
infection of two IMC expressing envelopes of transmitted/founder
viruses, WITO and CH58 (Figure S8). Thus, in addition to TGF-
b, Activin A activity may account for the broader inhibitory effects
of uterine epithelial cell CM on HIV-1 trans infection mediated by
DC. Future studies examining the mechanisms by which Activin A,
either singly or in synergy with TGF-b affect HIV-1 trans infection
will provide valuable insight about biology of sexual transmission.
An alternative explanation for the observed minimal inhibitory
effects of TGF-b1o ntrans infection of transmitted/founder viruses
could be the involvement of DC-SIGN-independent pathways
including the use of alternate HIV-1 capture/binding molecules
such as galactosyl ceramide (Gal-ceramide), DEC-205, DCIR
[69,70,71,72,73,74,75]. In our study, specific blockade of DC-
SIGN on DC had little or no effect on the trans infection of
transmitted/founder HIV-1 variants, suggesting the involvement
of alternate receptors in addition to DC-SIGN. That infection is
inhibited by epithelial cell CM suggests that secretions from
epithelial cells have the ability to inhibit the alternate capture
molecules utilized by transmitted/founder viruses.
Our findings indicate that epithelial cell CM inhibits trans
infection of HIV-1 constructs expressing envelopes of transmitted/
founder viruses more effectively than does TGF-b1. In other
studies, we obtained evidence of potentially important phenotypic
differences between commonly used ‘reference virus strains’ like
BaL and YU-2, and transmitted/founder HIV-1 variants. For
example, while Clade B transmitted/founder Envs utilize CCR5
as a co-receptor [6], we found that a panel of ten Clade B
transmitted/founder HIV-1 IMC, which we recently generated,
replicate poorly in monocyte-derived macrophages, and that this
maps to env (Ochsenbauer et al., unpublished observations). A
similar phenotype was observed for 3 Clade C transmitted/
founder IMC [9]. In contrast, the reference viruses BaL and YU-2
are highly macrophage-tropic. We do not infer that a lack of
macrophage tropism is the cause for the phenotype observed here,
but rather intend to highlight that certain phenotypic differences
between transmitted/founder viruses and commonly used refer-
ence viruses may and do exist, and that it is therefore important to
include the most relevant virus variants in transmission-related
studies. Our findings in the present study suggest that receptors on
DC through which reference and transmitted/founder HIV-1 trans
infection occurs may be separate and distinct. However, too little is
presently known about the biology of transmitted/founder HIV-1
envelopes to propose a mechanistic basis for our findings.
In conclusion, our study reports a novel mechanism by which
epithelial cells regulate HIV-1 infectivity in the endometrium. The
recognition that uterine epithelial cell secretions interfere with
DC-mediated trans infection of HIV-1 in the endometrium offers
new insight into potential novel strategies to block sexual
transmission of HIV-1 transmitted/founder viruses.
Materials and Methods
Isolation and Culture of Uterine Epithelial Cells (UEC)
All investigations involving human subjects were conducted
according to the principles expressed in the Declaration of Helsinki.
Approval to use human endometrial tissues in this study was
previously obtained from the Committee for the Protection of
Human Subjects, Dartmouth Hitchcock Medical Center (DHMC),
and written informed consent was obtained from the patients before
surgery. Primary UEC were isolated from endometrial tissues of
patients undergoing hysterectomy at DHMC. Primary UEC were
then cultured to establish polarity with apical and basolateral
compartments as previously described [55]. Briefly, following
enzymatic digestion to isolate epithelial cells from uterine tissues,
cells were washed, resuspended in complete DMEM/F12 medium
without phenol red (Invitrogen Life Technologies, Carlsbad, CA)
supplemented with 20 mM HEPES, 2 mM L-glutamine (Invitro-
gen Life Technologies, Carlsbad, CA), 50 mg/mL primocin
(Invivogen, San Diego, CA, USA) and 10% heat-inactivated
Figure 4. Lack of TGF- b1 inhibition of DC-mediated trans
infection of transmitted/founder HIV-1 variants. Shown is the
effect of recombinant TGF-b1 (10 ng/mL) on trans infection of HIV-1
infectious molecular clones (env-IMC) envelope ectodomains reference
env (BaL or YU-2) (A) or transmitted/founder env variants (B)b yD C
(n=5 blood donors). HIV-1 trans infection assay was performed using
TZM-bl reporter cells as targets as described in materials and methods.
Unshaded histograms are Control DC and the black histograms are TGF-
b1 DC. The data are presented as % transmission 6 SEM (Calculated
from 4 or 5 separate experiments: see Table 2) of HIV-1 by TGF-b1D C
relative to Control DC. * p,0.05. n.s indicates not significant (p.0.05).
doi:10.1371/journal.pone.0014306.g004
HIV Trans Infection of DC
PLoS ONE | www.plosone.org 7 December 2010 | Volume 5 | Issue 12 | e14306defined Fetal Bovine Serum (FBS) (Hyclone, Logan, UT, USA).
Cells were then analyzed for cell number and viability. On average,
isolated primary UEC are cultured on inserts for two weeks to
ensure tight junction formation, which typically occurs in 7–10 days
[76]. Upon attainment of high TER, the apical and basolateral
compartments were washed 4 times with complete DMEM/F12
medium. Cells with high TER were further cultured in complete
DMEM/F12 medium for 24 hr prior to the collection of apical and
basolateral conditioned medium (CM). The collected media were
centrifuged for 5 min at 10, 0006 g and stored at 280uC.
Basolateral CM harvested from polarized primary UEC after 24 hr
of culture was used in all DC cultures. Apical and basolateral CM
was collected from the confluent monolayers of UEC after 24 hr in
culture, and used in subsequent studies.
ECC-1, a well-differentiated uterine epithelial cell line [35] was
a gift from Dr George Olt, Penn State College of Medicine, Milton
S. Hershey Medical Center, PA. ECC-1 were cultured as
previously described to establish cellular polarity with apical and
basolateral compartments [22]. CM was collected from polarized
ECC-1 following 24 hr of culture and used in subsequent studies.
Isolation of Monocytes and Preparation of dendritic cells
(DC)
Immature DC were differentiated from human monocytes with
GM-CSF and IL-4 [77]. Briefly, monocytes were isolated from
human PBMC using CD14 microbeads (Miltenyi Biotec, Auburn,
CA). The purity of isolated monocytes was greater than 98% as
indicated by CD14 expression (anti-CD14 mAb, clone 61D3,
Ebioscience, San Diego, CA). Isolated monocytes were subse-
quently were cultured for 7 days with complete RPMI 1640
medium without phenol red (Invitrogen Life Technologies)
supplemented with 20 mM HEPES, 2 mM L-glutamine (Invitro-
gen Life Technologies), 50 mg/mL primocin (Invivogen, San
Diego, CA, USA) and 10% heat-inactivated defined FBS
(Hyclone). On day 0 of culture, cells were treated with GM-CSF
(50 ng/ml) and IL-4 (50 ng/ml) (PeproTech Inc). Thereafter,
cytokines were replenished every other day (i.e. days 2, 4 and 6).
On day 7 immature DC were harvested, counted and viable cells
resuspended for use in subsequent experiments.
To determine the effect of UEC CM on differentiation of
immature DC, human monocytes were cultured with IL-4 (50 ng/
mL) and GM-CSF (50 ng/mL) (PeproTech Inc) for seven days in
the presence or absence of CM obtained from ECC-1 or from
primary UEC. In all experiments, CM from ECC-1 and primary
UEC were used at 1:1 dilution with fresh complete RPMI medium
to avoid nutritional deprivation to the cells during the differen-
tiation process. In some experiments, TGF-b Receptor 1 blocker,
SB431542 (10 mM, Tocris Cookson Inc) [37] was simultaneously
added with CM for the entire duration of the differentiation. As
positive control for TGF-b effects, DC were differentiated with
increasing concentrations (0, 0.1 ng, 1 ng and 10 ng/mL) of
recombinant human TGF-b1 (PeproTech Inc).
Flow cytometry
Immature DC were stained with the following flourochrome-
labeled antibodies: DC-SIGN (Clone 120507), CCR5 (Clone
45531) and CXCR4 (Clone 12G5) (R&D (Minneapolis, MN).
Matched isotype controls for the antibodies were used to control
for non-specific binding. Following antibody staining, cells were
washed with staining buffer and fixed with 2% methanol-free
paraformaldehyde in 1X PBS (2% PFA), and then subsequently
analyzed on a Becton Dickinson FACS Calibur (San Jose, CA).
The acquired FACS data were analyzed with the Cell Quest
TM
software (BD).
TGF-b ELISA and Bioassay
TGF-b1 concentrations in the CM were analyzed with the
DuoSet ELISA kit (R&D Systems, Minneapolis, MN) according to
Table 2. Effect of Recombinant TGF-b1 on DC-mediated trans infection of HIV-1.
% Transmission (trans) of HIV-1 by TGF-b1D C
(Transmission by Control DC set at 100%)
Donor 1 Donor 2 Donor 3 Donor 4 Donor 5
Reference HIV-1
BaL 51.1 (5.1) 79.3 (2.7) 74.0 (3.1) 64.9 (9.0) 87.8 (1.1)
p value 0.019 0.033 0.045 0.010 0.021
YU-2 57.6 (3.4) 60.0 (4.9) 72.0 (11.7) 30.8 (7.5) 68.6 (15.0)
p value 0.010 0.042 0.039 0.026 0.012
Transmitted/Founder HIV-1
WITO 80.3 (8.1) 100.5 (20.1) 86.7 (9.5) 105.7 (20.5) 84.8 (6.5)
p value 0.089 0.478 0.216 0.410 0.026
CH058 69.3 (7.4) 120.7 (34.0) 90.4 (5.2) 65.6 (19.3) 72.1 (4.9)
p value 0.044 0.300 0.178 0.147 0.011
WEAU 78.6 (8.3) 107.7 (6.4) 91.6 (10.6) 92.3 (7.4) 56.8 (4.3)
p value 0.067 0.195 0.382 0.171 0.017
CH077 50.5 (5.9) 68.7 (2.1) 41.0 (1.3) ND 69.8 (7.8)
P value 0.019 0.010 0.013 0.045
Summarized data from individual experiments showing the effect of TGF-b1o ntrans infection of HIV-1 by DC. DC were differentiated in the presence or
absence of TGF-b1 (10 ng/mL). DC-mediated trans infection of HIV-1 infectious molecular clones (env-IMC) expressing reference env (BaL and YU-2) or transmitted virus
env (WITO, CH058, WEAU and CH077) respectively was determined using TZM-bl cells as targets for virus infection. Results are presented as percent transmission 6 SEM
of HIV-1 by TGF-b1 DC relative to Control DC (value set at 100%). ND, indicates not determined.
doi:10.1371/journal.pone.0014306.t002
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TGF-b in the CM was determined with the Mv1Lu mink lung
epithelial cell line as previously described [48].
HIV-1 trans infection assay
Viruses used were replication-competent infectious molecular
clones (IMC) of a modified NL4-3 backbone into which the env
Figure 5. Effect of Primary UEC CM, TGF-b1 and anti-DC-SIGN on HIV-1 trans infection assessed with NOMI T cell targets. The effect of
CM (A) and TGF-b1 (10 ng/mL) (B)o ntrans infection of HIV-1 infectious molecular clones (env-IMC) envelope ectodomains reference env (BaL or YU-
2) (i.e. Ref env) or transmitted/founder env variants (i.e. T/F env) is shown for a representative of two experiments. (C) shows the effect of anti-DC-
SIGN monoclonal antibody (25 mg/mL) on trans infection of IMC expressing Ref env and T/F env (a representative of 3 experiments). Experimental
details are described in materials section. Data are presented as % HIV-1 transmission 6 SEM (for triplicate analyses) relative to Control DC. * p,0.05,
ns indicates non significance.
doi:10.1371/journal.pone.0014306.g005
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including those of transmitted viruses [6,9] (Ochsenbauer et al,
in preparation). The nef-positive gfp-encoding NLENGIi-Env.ecto
viruses [39,40] and (Ochsenbauer et al in preparation) derived
from NLENGI-ires [39,78,79] express GFP upon infection which
was exploited to confirm the absence of DC cis-infection under the
given experimental conditions (data not shown). NL-LucR.T2A-
Env.ecto viruses express the Renilla luciferase reporter gene [40].
All env-IMC constructs expressed Env proteins in which the
ectodomains were derived from different primary viruses,
respectively, and the cytoplasmic domain of NL4-3 Env. The
strategy and the rationale of shuttling in the Env ectodomain
encoding sequences from select primary viruses into isogenic
reporter and non-reporter virus backbone has been described
[40,80]. Virus was produced on 293 T cells and titer was
established on TZM-bl cells as described [41]. HIV-1 trans
infection by DC was assayed with a modification of previously
described protocols [81,82]. Following differentiation of immature
DC for 7 days, cells were extensively washed and then pulsed with
HIV-1 for 2 hr. Unbound virus was removed by multiple wash
steps and DC then co-cultured with TZM-bl cells for 48 hr. Virus
infection of TZM-bl cells was determined by measuring beta
galactosidase activity following addition of Beta Glo substrate.
In some experiments, HIV-1 trans infection by DC was assayed
with T cells as target, utilizing the previously described reporter T
cell line, NOMI [43,44]. NOMI cells were maintained in RPMI
supplemented with 10% FBS. For these trans infection assays, DC
were pulsed for 2 hr with env-IMC expressing Renilla luciferase
reporter gene [40]. Following multiple wash steps to remove
unbound virus, DC were co-cultured with NOMI cells for 72 hr.
Virus infection of NOMI cells was then assessed by measuring
Renilla luciferase activity using commercial reagents (Promega,
Madison, WI). Additional control experiments were performed to
directly examine the involvement of DC-SIGN in DC mediated
trans infection of HIV-1. For these experiments, DC were pre-
treated with anti-DC-SIGN antibody (25 mg/mL, clone 120507
from R&D) for 30 minutes at 37uC prior to 2 hr incubation with
HIV-1.
Statistical Analysis
Statistical analysis was performed using unpaired t-test. One
way ANOVA followed by a Tukey multiple comparison
(GraphPad Prism Version 5.0; GraphPad Software Inc., San
Diego, CA) was used to determine differences between treatment
conditions. A value of p,0.05 was considered significant.
Supporting Information
Figure S1 ECC1 Conditioned medium (CM) decreases expres-
sion of DC-SIGN on Immature DC by TGF-b mechanism. (A)
Overlay histograms show expression of DC-SIGN by Control DC
(light gray) or DC differentiated with ECC-1 CM (dark gray).
Staining with isotype control antibody is shown as unfilled
histogram. Combined MFI values for DC-SIGN expression by
DC from multiple donors (n=5) are presented as % MFI of
Control DC 6 standard error of mean (SEM). * indicates
p=0.035. (B) Blockade of TGF-b signaling abolishes the effect of
ECC-1 CM on DC-SIGN expression. TGF-b was blocked with
the TGF-b Receptor 1 antagonist (SB431542). Combined MFI
values (n=3 donors) are presented as % MFI of Control DC 6
SEM. * indicates p,0.009 compared to control DC.
Found at: doi:10.1371/journal.pone.0014306.s001 (0.10 MB TIF)
Figure S2 Acute treatment of DC with uterine epithelial cell
CM down-regulates DC-SIGN expression. Monocytes were
cultured in IL-4 (50 ng/mL) and GM-CSF (50 ng/mL) for 7
days. Immature DC were cultured for additional 48 hr in the
absence or presence of ECC-1 CM (A) or primary UEC CM (B).
Results are presented as % MFI DC-SIGN expression relative to
Control DC. * indicates p,0.05 (n=3 donors).
Found at: doi:10.1371/journal.pone.0014306.s002 (0.00 MB TIF)
Figure S3 TGF-b1 Secretion by Uterine Epithelial Cells. TGF-
b1 was measured in basolateral and apical supernatants obtained
from primary uterine epithelial cells (n=5) following 48 hr of
culture. Active TGF-b1 was measured directly while total TGF-b1
was assayed following an activation step with HCL. Data show
mean 6 standard error of mean (s.e.m) of TGF-b1 in either the
apical or basolateral chamber of the Transwell tissue culture
insert. * Indicates significant difference (p,0.05) from secretion
into the apical chamber.
Found at: doi:10.1371/journal.pone.0014306.s003 (0.01 MB TIF)
Figure S4 Biological activity of TGF-b produced by primary
uterine epithelial cells (UEC). The activity of TGF-b was
determined as previously described [39]. (A) Standard curve
generated with increasing doses of recombinant TGF-b1. Shown is
a dose-dependent induction of PAI-1 (plasminogen activator
inhibitor-1) in Mink lungs epithelial cells (MLECs) by TGF-b1.
(B) High concentration (TGF-b1, 10 ng/mL) induces PAI-1
expression in MLECs. The effect is blocked by treating the cells
with SB431542 (10 mM). Included are baseline inductions of PAI-1
in MLECs by DMEM in the absence (Medium) or presence
(Medium-Block) of SB431542. (C) Effect of primary UEC CM on
PAI-1 (Plasminogen activator inhibitor 1) expression. MLECs
were cultured overnight in the presence (UEC CM) or absence
(Medium) of primary UEC CM (n=5) obtained from basolateral
compartment of polarized epithelial cells. The specificity of this
effect was determined by treating the cells with SB431542 (UEC
CM-Block). Data are presented as mean Relative light units (RLU)
of luciferase activity 6 standard error of mean (SEM).
Found at: doi:10.1371/journal.pone.0014306.s004 (0.08 MB TIF)
Figure S5 Uterine epithelial cell conditioned medium (CM)
increases surface expression of CXCR4 on Immature DC.
Overlay histograms for the expression of CXCR4 (A) and
CCR5 (B) by Control DC or DC differentiated with primary
UEC Conditioned medium (CM) for 7 days. The unfilled
histogram shows staining with matched isotype antibody. Com-
bined MFI values for DC-SIGN expression by DC from healthy
donors (n=4) that have been differentiated in the presence (black
bar) or absence (white bar) of UEC CM. Data is presented as %
MFI of Control DC 6 standard error of mean (sem). * p,0.05, n.s
denotes not significant (p=0.062).
Found at: doi:10.1371/journal.pone.0014306.s005 (0.28 MB TIF)
Figure S6 Relatively low productive infectivity of DC with HIV-
1. DC cells (26105) were incubated with 36105 infectious units
(IU) of HIV-1 infectious molecular clones (env-IMC-LucR)
expressing reference HIV-1 envelopes (BaL or YU2) (A) or
envelopes of transmitted/founder variants (B) with Renilla
luciferase reporter gene. For comparison, infection of TZM-bl
cells with HIV-1 encoding BaL or YU-2 env is shown (C).
Following 3 days of incubation, cells were lysed with 1X lysis
buffer and luciferase activity was determined with commercial
reagents (Promega, Madison, WI). Results are presented as mean
6 SEM of luciferase activity (LucR) after blank correction (RLU
of blank =168.60). The bold dashed line shows 2.5-fold change in
luciferase activity above background which is considered signifi-
cant. *p,0.05.
Found at: doi:10.1371/journal.pone.0014306.s006 (0.02 MB TIF)
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infection assay. (A) DC were incubated for 1 hr in the presence
or absence of Nevirapine (10 mM) and T20 (10 mg/mL) prior to
incubation with infectious molecular clones (env-IMC) expressing
envelope proteins of BaL or YU2 (56104 IU). DC were then
washed and co-cultured with TZM-bl. (B) DC were infected with
BaL env or YU-2 env expressing env-IMC for 2 hr and then co-
cultured with TZM-bl (2.56105) in the presence or absence of
T20 (10 mg/mL). C) DC were incubated for 1 hr in the presence
or absence of AMD-3100 (1.2 mM) and TAK-779 (10 mM). The
cells were washed extensively prior to infection with BaL env
expressing env-IMC for 2 hr. DC were then washed and co-
cultured with TZM-bl. In all cases, virus infection of TZM-bl cells
was then assayed by measuring b-galactosidase expression. Results
are presented as mean Relative Light Units (mean 6 SEM) of b-
galactosidase activity (beta-Gal RLU).
Found at: doi:10.1371/journal.pone.0014306.s007 (0.01 MB TIF)
Figure S8 Effect of Activin A treatment on trans infection of
HIV-1 by DC. DC were generated from human monocytes in the
absence (Control DC) or presence of recombinant Activin A
(100 ng/mL, ie. Activin DC). Following 7 days of differentiation,
DC were pulsed with HIV-1 infectious molecular clones (env-
IMC-LucR) expressing envelope ectodomains of reference HIV-1
(BaL or YU-2) (A) or transmitted/founder variants (B) for 2 hr and
then co-cultured with NOMI cells for 3 days. Virus replication in
NOMI cells was determined by measuring Renilla luciferase
activity. Unshaded histograms are Control DC and the black
histograms are Activin A treated DC. The data are presented as %
transmission 6 SEM (for triplicate analyses of a single experiment)
of HIV-1 by Activin DC relative to Control DC.
Found at: doi:10.1371/journal.pone.0014306.s008 (0.00 MB TIF)
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